Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements

摘要: Approximately 2–5% of non-small-cell lung cancers (NSCLC) contain rearrangements in the ALK gene. These tumors most frequently occur younger, never or light smokers with adenocarcinoma and are typically independent EGFR KRAS mutations. Crizotinib is a small molecule inhibitor tyrosine kinase that has demonstrated clinical activity advanced rearranged NSCLC patients response rate 51–61% Phase I II study an estimated median progression-free survival approximately 10 months. On basis this data US FDA approved crizotinib for treatment August 2011. In article we review pathologic features associated gene NSCLC, diagnostic assays rearrangements, safety efficacy crizotinib, outline remaining challenges population including problem acquired resistance.